source
- Novartis' Zolgensma linked to tumors as FDA probes gene therapy and orders GLP-1 eye risk warningsNovartis confirmed that nine patients who received its Zolgensma gene therapy for spinal muscular atrophy have developed tumors, prompting the FDA to open an investigation into the approved treatme…
- China’s five-year plan positions it to become a global leader in innovative biopharma by 2030China’s latest five‑year plan sets an ambitious target to turn the country into a major source of innovative medicines for the world market. Experts cited by BioSpace say the goal is within reach,…